Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Tuberculosis Vaccine Treatment Market Share

ID: MRFR//1152-HCR | 100 Pages | Author: Rahul Gotadki| April 2024

The market for treating tuberculosis by a vaccine is an important part of pharmaceutical industry because it addresses the global health challenge posed by tuberculosis (TB). The determinants of success in this space are based on how companies position themselves with regard to market share. One of them includes innovation in vaccine development. This enables firms to engage in R & D aimed at developing and implementing more effective TB vaccines differentiating themselves from competitors. Therewith, such need not only contributes to gaining a competitive edge but also helps to address emergent character of TB bacteria as well as appearance of drugs inactive bacterium strains.

Equally, partnerships and alliances play a significant role in positioning companies for best market share within the Tuberculosis Vaccine Treatment Market. For instance, businesses can get together with research institutions, non-profit organizations and governmental agencies in order to benefit from shared expertise, resources, and funding. Apart from speeding up the process of vaccine development these collaborations boost credibility across the companies involved thereby fostering positive market perception about their products. In addition, establishing strong relations with international health bodies like World Health Organization (WHO) helps establish company’s position at both national and international levels.

In cases where there are several players competing for market share on tuberculosis vaccines; access and affordability becomes very critical. A company can gain substantial market share if it adopts pricing strategies that make its products affordable and accessible to majority of people living in areas highly populated with TB due to socio-economic disparities that exist between different regions . By using tiered pricing models, differential pricing strategies for various regions and engaging actively in global campaigns aimed at reducing costs of vaccines through price discrimination mechanisms such firms are able to assert their dominance in diverse markets.

Also important is having a successful distribution network if one wants to succeed within the Tuberculosis Vaccine Treatment Market. Companies should place their commodities strategically so that they reach most people affected by TB faster through effective distribution channels. This involvement could result into partnership agreements with local health care providers, government health agencies and non-governmental organizations which help in bringing vaccines to remote and underserved areas thereby increasing market share.

Finally, public education campaigns are critical elements of any marketing strategy intended to be used for positioning tuberculosis vaccines’ market share. This not only contributes to disease knowledge of people but also enhances corporate reputation through participation in public health awareness programs. Educated individuals are more likely to seek immunization and thus by being associated with advocacy organizations companies play a key role in shaping the attitude of the public while creating obligations towards TB prevention.

Tuberculosis Vaccine Treatment Market Scenario:


The tuberculosis vaccine treatment market is projected to reach USD 80.08 Million by 2030 at 5.67% CAGR during the forecast period 2022-2030.Tuberculosis (TB) is an infectious disease which is caused by the bacteria called Mycobacterium tuberculosis (MTB). Tuberculosis mainly affects lungs, but can also affect other parts of the body. Typical signs of tuberculosis includes chronic or persistent cough and sputum production. When TB is at an advanced stage the sputum will contain blood and other symptoms include lack of appetite, weight loss, fever, and night sweats.


 The vaccines trigger a potent immune response against infectious diseases; tuberculosis (TB) vaccines prevent infection with tuberculosis. Robert Koch was first to propose immunotherapy as a defense mechanism against TB. Currently, the only effective tuberculosis vaccine is BCG (Bacilli Calmette-Guerin).


Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of the Tuberculosis Vaccine Treatment Market. Furthermore, improving healthcare infrastructure and emphasis on prevention of diseases drive the growth of Tuberculosis Vaccine Treatment Market.


According to Centers for disease control and prevention, One third of the world’s population is infected with TB. In 2016, 10.4 million people around the world became sick with TB disease. There were 1.7 million TB-related deaths worldwide. A total of 9,272 TB cases (a rate of 2.9 cases per 100,000 persons) were reported in the United States in 2016.


However, on the other hand, side effects occurring from the vaccinations and the government approval time for the vaccine are the major factors that may hinder the growth of the Tuberculosis Vaccine Treatment Market.


Intended Audience



  • Research and Development (R&D) Companies

  • Government and Independent Research Laboratories

  • Tuberculosis Vaccines Manufacturers

  • Tuberculosis Vaccines Suppliers

  • Government and Independent Regulatory Authorities

  • Academic Medical Institutes and Universities


Figure 1- Tuberculosis vaccine treatment market, by type of TB test tuberculosis vaccine treatment market


    Annual reports, press release, white paper, company presentation 


Segmentation


Tuberculosis vaccine treatment market is segmented on the basis of types of test, type of TB vaccines, and end users.


On the basis of type of test, it is segmented into tuberculin skin test (TST), TB blood tests, IGRAs (interferon-gamma release assays), and others.


On the basis of type of Tb vaccines, it is segmented into immunotherapeutic vaccines, booster vaccines, and others.


And on the basis of end users, it is segmented into hospitals, private clinics, research institutes, and others.  


Regional Analysis On the regional basis, the tuberculosis vaccine treatment market is segmented into America, Europe, Asia Pacific and the Middle East & Africa.


America holds the largest market share of TB vaccines due to the major market players are concentrated and its emphasis on vaccination against TB.


Europe accounts for the second largest market for TB vaccines; this is due to increase in research and development activities by research institutions and pharmaceutical companies. According to UK TB statistics reports, in 2016 there were 5,664 TB cases 39% of cases were in diagnosed in London and 3.8% of people with TB were also living with HIV.


Asia Pacific is expected to be the fastest growing market for Tuberculosis vaccines market over the forecast period. India and China are expected to be emerging and fastest growing countries in this regional market.


According to WHO, India accounts with the highest burden of TB. In 2015, an estimated incidence of 2.84 million cases of TB in India.


On the other hand, The Middle East and Africa holds least market share due to limited screening, ignorance of diseases, and poor access to treatment.


Key Players Merck & Co., Inc.(US), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), GlaxoSmithKline plc (UK), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(US), Solvay(US), Informa plc.(US) and others. 


Market Assessment


Tuberculosis Vaccine Treatment Market-


Annual reports, World Health Organization (WHO), white paper, company presentation

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.